Lanabecestat

Ligand id: 7789

Name: Lanabecestat

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 72.86
Molecular weight 412.23
XLogP 4.56
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane-1,2'-inden-1',2'-imidazol)-4'-amine
International Nonproprietary Names
INN number INN
10530 lanabecestat
Synonyms
AZD 3293 | AZD-3293 | LY3314814
Database Links
PubChem CID 67979346
Search Google for chemical match using the InChIKey WKDNQONLGXOZRG-BOPKNSRXSA-N
Search Google for chemicals with the same backbone WKDNQONLGXOZRG
Search PubMed clinical trials lanabecestat
Search PubMed titles lanabecestat
Search PubMed titles/abstracts lanabecestat
Search UniChem for chemical match using the InChIKey WKDNQONLGXOZRG-BOPKNSRXSA-N
Search UniChem for chemicals with the same backbone WKDNQONLGXOZRG
Wikipedia AZD3293
Comments
Lanabecestat (AZD3293) is an oral, potent and selective small molecule inhibitor of BACE1 being developed by AstraZeneca and Eli Lilly [4] . It is now proceeding to Phase III trials [3]. Note our initial chemical assignment was based on the crystallisation data in US20140031379 [2] but the name is now attached to two CIDs, the one designated in this entry with correct stereoisomer and the flat form as PubChem CID 57404290